Pemirolast ophthalmic - Santen

Drug Profile

Pemirolast ophthalmic - Santen

Alternative Names: Alamast; Alegysal; BMY 26517; DE 068; Pemilaston; Pemirolast ophthalmic; Pemirolast potassium

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb; Mitsubishi Tanabe Pharma Corporation
  • Class Antiallergics; Antiasthmatics; Nonsteroidal anti-inflammatories; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Allergic conjunctivitis; Seasonal allergic rhinitis

Most Recent Events

  • 07 Mar 2011 Mitsubishi Tanabe Pharma Corporation transfers marketing rights of Alegysal® to its subsidiary, Tanabe Seiyaku Hanbai
  • 24 May 2004 Launched for Allergic conjunctivitis in China (Ophthalmic)
  • 24 May 2004 Launched for Allergic conjunctivitis in Philippines (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top